Literature DB >> 10980735

Short-term prognosis in early relapsing-remitting multiple sclerosis.

T F Scott1, C J Schramke, J Novero, C Chieffe.   

Abstract

OBJECTIVE: To characterize a group of patients with early MS using prognostic factors and to determine whether these prognostic factors impact on short-term prognosis.
METHODS: Data were collected prospectively on 98 patients newly diagnosed with MS in our MS clinic between 1990 and 1998 (average follow-up, 37 months from the time of onset of clinically definite MS [CDMS]). Six prognostic factors were recorded: age at onset, symptoms at onset, MRI status at onset and at diagnosis of CDMS, interval between the first and second attack, attack frequency in the first 2 years, and completeness of recovery from initial attacks. Completeness of recovery was determined using Expanded Disability Status Scale scores (EDSS). Progression was determined by final EDSS and changes in EDSS between initial presentation and final follow-up.
RESULTS: Patients predicted to have low risk of progression of MS based on the prognostic factors represented 17% of our patient population (0 to 1 risk factor for progression). The patients with high risk of progression (4 to 6 risk factors) represented 24% of patients. Patients with a high number of risk factors did significantly worse than those with a small or medium number of risk factors in terms of final EDSS and progression to higher EDSS. At the time of diagnosis of CDMS, MRI findings suggestive of MS were seen in 84% of patients (suspicious in 13%, negative in 3%).
CONCLUSION: Short-term prognosis was influenced by the presence or absence of a high number of these six risk factors.

Entities:  

Mesh:

Year:  2000        PMID: 10980735     DOI: 10.1212/wnl.55.5.689

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

Authors:  A Martínez-Yélamos; A Rovira; R Sánchez-Valle; S Martínez-Yélamos; M Tintoré; Y Blanco; F Graus; X Montalban; T Arbizu; A Saiz
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

Review 2.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

3.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Authors:  Amit Bar-Or; Ralf Gold; Ludwig Kappos; Douglas L Arnold; Gavin Giovannoni; Krzysztof Selmaj; John O'Gorman; Monica Stephan; Katherine T Dawson
Journal:  J Neurol       Date:  2013-09       Impact factor: 4.849

4.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Authors:  Michael Hutchinson; Robert J Fox; David H Miller; J Theodore Phillips; Mariko Kita; Eva Havrdova; John O'Gorman; Ray Zhang; Mark Novas; Vissia Viglietta; Katherine T Dawson
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

5.  CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.

Authors:  Scott D Newsome; Philip J Aliotta; Jacquelyn Bainbridge; Susan E Bennett; Gary Cutter; Kaylan Fenton; Fred Lublin; Dorothy Northrop; David Rintell; Bryan D Walker; Megan Weigel; Kathleen Zackowski; David E Jones
Journal:  Int J MS Care       Date:  2016 Nov-Dec

6.  Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Authors:  Tobias Derfuss; Daniel Ontaneda; Jacqueline Nicholas; Xiangyi Meng; Kathleen Hawker
Journal:  Mult Scler Relat Disord       Date:  2016-05-24       Impact factor: 4.339

7.  Demyelinating events in early multiple sclerosis have inherent severity and recovery.

Authors:  E M Mowry; M Pesic; B Grimes; S Deen; P Bacchetti; E Waubant
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

8.  MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Authors:  Giancarlo Comi; Stuart D Cook; Gavin Giovannoni; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony C Hamlett; Vissia Viglietta; Steven J Greenberg
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

9.  Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Guillermo Izquierdo; Bhupendra Khatri; Xavier Montalban; Jean Pelletier; Benjamin Eckert; Dieter A Häring; Gordon Francis
Journal:  J Neurol       Date:  2013-04-30       Impact factor: 4.849

10.  Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.

Authors:  Michael Gurevich; Tamir Tuller; Udi Rubinstein; Rotem Or-Bach; Anat Achiron
Journal:  BMC Med Genomics       Date:  2009-07-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.